How an Infusion Billing Audit Recovered $180,000 in Hidden Oncology Revenue

Infusion Billing errors are not always outright denials on a report. Some losses never trigger a denial at all. Underpayments, write-offs, and drug cost gaps often hide in plain sight. These errors quietly drain revenue without ever showing up as rejected. A full Infusion Billing audit is often the only way to find them. At Infusion Billing Services, we recently completed a full audit for a client. Their oncology practice had never reviewed billing beyond standard denial reports. This case study explains the five Infusion Billing errors we uncovered. Together, these errors had cost the practice $180,000 over one year.

Client Snapshot

Our client was a mid sized oncology infusion practice with two locations. They administered roughly 700 chemotherapy infusion visits each month. Monthly chemo drug spend under buy and bill exceeded 300,000 dollars. The payer mix included Medicare, commercial insurance, and Medicare Advantage plans. Commercial payers accounted for close to 46% of total claim volume. We conducted a full twelve month audit across drug inventory and claims data. This went well beyond the practice’s normal denial tracking reports. Standard reports had shown a denial rate of just 11%. The full Infusion Billing audit revealed $180,000 in losses that denial tracking never captured.

Infusion Billing Error 1: Chemo Drug Wastage Never Reported or Recovered

Single dose chemo vials often contain more drugs than one patient needs. CMS requires the JW or JZ modifier to report this difference. Many claims were missing this modifier on chemo drug charges entirely. This meant the purchased drug cost was never billed to the payer.

Problem:

• Discarded chemo drug was never reported with a modifier
• Purchased drug cost exceeded what was actually billed
• Wastage tracking was not tied to inventory draw records

Fix:

• Built a wastage capture process tied to inventory draw
• Required JW or JZ modifiers on every applicable claim
• Reconciled purchased drug against billed drug regularly

This single fix recovered the largest share of the $180,000 in losses.

Infusion Billing Error 2: Incorrect Infusion Hierarchy Sequencing

Multi drug chemo visits follow a strict initial, sequential, and concurrent hierarchy. The highest paying code must be billed as the initial service. Several claims did not follow this hierarchy correctly during coding. This caused the practice to bill a lower paying code as primary, a common Infusion Billing error that rarely triggers a denial.

Problem:

• Highest paying code was not billed as the initial service
• Hierarchy rules were not applied consistently across visits
• Multi drug visits were coded without a clear sequencing process

Fix:

• Standardized hierarchy based coding logic for chemo visits
• Reviewed drug sequence before assigning the initial code
• Trained coders on correct hierarchy rules for multi drug visits

Correcting hierarchy sequencing recovered revenue lost to silent underbilling.

Infusion Billing Error 3: Missing Modifier 25 on Same Day Oncology Visits

Patients sometimes had a separate office visit on the same day. Without modifier 25, this visit bundled into the chemo administration charge. This meant evaluation and management revenue went completely unbilled. Documentation often supported a separate visit that this Infusion Billing gap left uncaptured.

Problem:

• Office visit was billed without the required modifier 25
• Documentation supported a separate visit that went unbilled
• Same day visits were bundled into the infusion charge by default

Fix:

• Required modifier 25 review on every same day visit
• Documented the separate reason for the office visit clearly
• Reviewed same day claims for completeness before submission

This fix recovered visit revenue that had been lost to bundling.

Infusion Billing Error 4: ASP Pricing and Unit Conversion Errors

Chemo drugs are billed using average sales price based HCPCS descriptors. Units must be calculated precisely against the descriptor and vial size. Several claims miscalculated these units, resulting in silent underbilling. No denial occurred, since the claim was still technically valid, making this Infusion Billing error especially hard to catch.

Problem:

• Billed units did not match the ASP based HCPCS descriptor
• Vial size was not factored correctly into unit calculations
• Underbilling occurred without triggering any claim denial

Fix:

• Built a unit conversion audit for every high cost drug
• Compared billed units against descriptor and vial size
• Corrected calculations before claims left the office

This audit uncovered underbilling that standard reports never flagged.

Infusion Billing Error 5: Delayed or Incomplete Prior Authorization for Biologics

High cost biologic chemo agents require thorough prior authorization. Several treatments were administered before authorization was fully confirmed. This led to full write-offs on some of the most expensive claims. These losses represented one of the costliest Infusion Billing errors in the audit.

Problem:

• Biologic agents were administered before authorization confirmed
• Incomplete authorization led to full claim write-offs
• High cost claims carried the largest financial exposure

Fix:

• Built a pre treatment authorization confirmation step
• Required biologic authorization confirmed before scheduling
• Reviewed authorization status before every high cost visit

Preventing early administration protected the practice’s highest value claims.

How the $180,000 in Losses Was Identified

Standard denial reports only capture claims that are actively rejected. This audit reviewed drug inventory, coding logic, and claims data together. Comparing purchased drug against billed drug revealed the wastage gap first. Reviewing hierarchy and unit calculations uncovered silent underbilling next. Prior authorization records were then cross checked against treatment dates. This step surfaced write-offs that had never been formally tracked. Each category was quantified separately to build the full $180,000 total. This process took six weeks to complete across the full year of data.

Financial Recovery Results

The table below shows the loss breakdown and the improvement achieved. These results reflect what a full spectrum Infusion Billing audit can uncover.

These losses had never appeared on a standard denial report. Only a full Infusion Billing audit surfaced the complete financial picture. This confirms why denial rate alone is not a full measure of revenue health.

Key Takeaways

• Infusion Billing losses often hide outside standard denial reports
• Drug wastage tracking protects revenue tied to buy and bill spend
• Hierarchy sequencing directly affects which code pays the most
• ASP unit errors can cause silent underbilling without any denial
• Prior authorization gaps create the largest single claim losses

Conclusion

Infusion Billing errors are not limited to claims that get denied. Wastage, sequencing, modifiers, units, and authorization all carry hidden risk. As this case shows, a full audit uncovered $180,000 in prior losses. Preventing these errors going forward protects revenue the practice already earns.

If your practice has never audited billing beyond denial reports, we can help. Infusion Billing Services conducts full spectrum audits across drugs, coding, and claims. Hidden losses often exceed what standard denial tracking ever reveals.

Contact Infusion Billing Services today for a complete Infusion Billing audit. Start uncovering revenue your practice may not know it is losing.